Prostate cancer injection Capaban launched by Panacea Biotec

Published On 2016-03-29 04:57 GMT   |   Update On 2016-03-29 04:57 GMT

New Delhi: Drug firm Panacea Biotec launched Cabapan injection, an indigenously developed drug for treating prostate cancer.


Used in the treatment of metastatic castration resistant prostate cancer, it has been developed by the company at its Mumbai-based R&D Centre in compliance with the global current good manufacturing practices (cGMP), Panacea Biotec said in a regulatory filing.


The company is manufacturing the product at its Baddi, Himachal Pradesh-based manufacturing facility, it added.


"The launch of Cabapan reflects the hard work of Panacea Biotec's scientists who worked tenaciously for the development of this drug," Panacea Biotec Joint Managing Director Rajesh Jain said.


Prostate is the second leading site of cancer amongst males in India.


Panacea Biotec shares were trading over 2 per cent down at Rs 95 apiece on BSE.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News